FcRn inhibitors, such as efgartigimod, have been developed and are currently under clinical assessment for the treatment of myasthenia gravis, primary immune thrombocytopenia and pemphigus vulgaris/foliaceus. This evidence concerns the gene FCGRT and pemphigus vulgaris.